PARP1 might enhance the therapeutic effect of tetrahydroxystilbene glucoside in traumatic brain injury via inhibition of Ras/JNK signalling pathway

Yiqiang Cao¹, Yu Chen², Fei Wang¹, Yonggang Wang¹, Jiang Long¹
¹Department of Neurosurgery, the First Affiliated Hospital of Kunming Medical University, Kunming, China, ²Department of Neurosurgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Abstract
Trauma is the main cause of death for people aged 1-45, and among them, traumatic brain injury (TBI) is the major condition, which causes over 50,000 deaths each year and costs over 80 billion per year. Tetrahydroxystilbene glucoside (TSG) is the active ingredient of polygonum multiflorum, a traditional Chinese herbal medicine, which presented multiple pharmacological effects, including antioxidative, anti-inflammatory, reducing blood fat and neuroprotection effects. However, the effect of TSG in promoting the recovery of the nerve system after TBI is not fully understood. PARP1 is a key enzyme in repair of the damage in DNA, which is activated by binding to DNA breaks, initiating both single-strand and double-strand DNA break repair. And we thought that overexpression of TSG might enhance the effect of TSG in TBI treatment. In this study, we firstly detected the oxidative stress response related molecules in serum samples of TBI patients and a TBI mice model, and found that oxidative stress response was activated after TBI, and TSG would reduce this effect. We further noticed that inflammation related molecules presented a similar trend with oxidative stress response related molecules. These results indicated that inflammatory response and oxidative stress processes were both activated after TBI, and reduced after TSG treatment. We further detected that the apoptosis related proteins and anti-oxidative proteins were increased after TSG treatment, and these effects were enlarged after overexpression of PARP1. We further noticed that these effects might be mediated by inhibition of the Ras/JNK signalling pathway. Thus, we thought overexpression of PARP1 might enhance the therapeutic effect of TSG in TBI treatment.

Key words: PARP1, tetrahydroxystilbene glucoside, traumatic brain injury, Ras/JNK signalling pathway.

Introduction
Traumatic brain injury (TBI) is one of the major causes of death and disability around the world. According to a previous study, the annual incidence of TBI is 10 million cases of death with the prevalence of 3.17 million of long-term TBI-induced disability, and it causes an economic burden of billions of dollars [15,24]. These disabilities are not only the mechanical damage caused by the initial injury, but are also caused by subsequent cellular and molecular damage in following days [29]. Tetrahydroxystilbene glucoside (TSG) is the main component of polygonum multiflorum, performs strong anti-oxidative and free radical-scavenging activities, and presented a variety of functions in previous studies, especially...
in cardiovascular protection and neuroprotection [37]. PARP1 is the first member of the PARP family, which was identified in 1987 [1]. PARP1 could detect the breaks in DNA strand and activate cellular DNA damage response through the activation of downstream biological process, including DNA damage repair, epigenetic regulation, transcription, apoptosis, and mRNA metabolism [20].

In the present study, we firstly noticed that the oxidative stress response was activated in TBI patients and a TBI mice model, and TSG treatment would reduce this effect. Besides, we also noticed that the expression of inflammatory response related molecules was increased and TSG treatment would also decrease the expression of these molecules. Besides, the expression of apoptosis related proteins and anti-oxidative enzymes was increased after TSG treatment, and these effects might be mediated by inhibition of the Ras/JNK signalling pathway, while overexpression of PARP1 would enlarge these effects and inhibition of PARP1 expression would reduce these effects. According to these results, we thought that overexpression of PARP1 might be a new therapeutic target in TBI treatment.

Material and methods

NOS (ab106535, 30), NOX4 (ab154244, 67), Catalase (ab16731, 60), TRX (ab26320, 12), Bcl-2 (ab182858, 26), Cleaved Caspase-3 (ab2302, 17), Caspase-9 (ab202068, 46), Rho (ab40673, 21), Ras (ab52939, 21), Rac1 (ab33186, 21), p-MEK1 (ab138662, 164), MEK1 (ab212601, 164), p-MK4 (ab25958, 44), MKK4 (ab33912, 44), JNK (ab208035, 48) and p-JNK (ab219584, 48) were purchased from Abcam. ROS/Superoxide Detection Assay (ab ab186027), Superoxide Dismutase 1 ELISA (ab119520), Lipid Peroxidation (MDA) Assay (ab233471) and NADP/NADPH Assay (ab65349) were purchased from Abcam.

Vector construction

Full length of PARP1 cDNA was cloned with the PCR method using the following primer: Forward: 5’-AGGCAATGCTAGC-3’, Reverse: 5’-CCA GCGGAACCTCTACAC-3’. pLenti-CMV-GFP blank vector was digested with BamHI (R31365, NEB) and Sall (R3138S, NEB), and connected with PARP1 cDNA using T4 ligase (M0201S, NEB). PARP1 knockdown vector was constructed according to the previous protocol [17]. Briefly, lentiviral CRISPR plasmid was firstly digested with BsmBI (R05805, NEB), and oligos were composed with the following primer: Forward: 5’-CACCAGTTTCATGCGCCATGTCTGTA-3’, Reverse: 5’-CTCAACATGGGCGACTCGAACAA-3’. Then, PARP1 knockdown vector was obtained using Quick Ligase (NEB M2200S). After vectors were constructed, vectors were transfected into 293T cells (CRL-11268, ATCC) to construct lentiviral vector after being incubated for 48 h, lentiviral vectors were injected into the mice model to construct a PARP1 overexpression mice model and PARP1 knockdown mice model.

Animal model

20 C57BL mice aged 5-8 weeks old and weighing 24.5-26.2 g were purchased from the Experimental Animal Centre of the Third Military Medical University (Chongqing, China). Animals were housed at 26°C, 55% humidity atmosphere with 12 h light/12 h dark cycle. Food and water were freely available. And mice were divided into four groups: CCI (Controlled Cortical Impact) group (CG, n = 5), CCI group combined with TSG treatment group (CT, n = 5), CCI group combined with TSG treatment and PARP1 inhibition group (CI, n = 5) and CCI group combined with TSG treatment and PARP1 overexpression group (CO, n = 5). Mice in the CCI group were used as a control group.

CCI model construction

The CCI model was constructed according to a previous study [30]. Briefly, mice were firstly anesthetized with 4% isoflurane inhalation. And CCI was performed after midline incision and craniotomy with a fabricated impactor (L. Kopacz, Germany; tip diameter, 3 mm; impact velocity, 8 m/sec; impact duration, 150 ms; impact depth, 1 mm). Then, craniotomy and skin were closed and animals were kept as previously described, and treated with 12 mg/kg TSG for seven days by an intraperitoneal injection [39]. After treatment, brain tissues and serum samples were collected to perform the following experiments.

Ethical statement

This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (USA). The protocol was approved by the Committee on the Ethics of Animal Experiments of the First Affiliated Hospital of Kunming
PARP1 might enhance the therapeutic effect of tetrahydroxystilbene glucoside in traumatic brain injury via inhibition of Ras/JNK signalling pathway.

Medical University. All experiments were conducted in accordance with the Declaration of Helsinki and were approved by the Ethics Committee of the First Affiliated Hospital of Kunming Medical University. All study participants gave written informed consent.

**RNA extraction and reverse transcription**

RNA extraction was performed according to the protocol (CW0560S, CWbio). Briefly, tissues were lysed with lysis buffer and incubated at room temperature for 5 min. After being centrifuged at 12,000 rpm for 5 min and mixed with 70% ethanol, the mixture was removed into an absorption tube. After being washed with washing buffer, RNAs were eluted from the tube using elution buffer. Then, reverse transcription was performed according to the protocol (CW0741, CWbio). Briefly, the reaction mixture was composed as recommended, and incubated at 42°C for 30 min followed with incubation at 85°C for 5 min. The cDNAs were stored at –20°C until the following experiments.

**Real-time quantitative polymerase chain reaction (qPCR)**

qPCR was performed according to the protocol (CW0957, CWbio). Briefly, the reaction mixture was composed as recommended. qPCR was performed using the following primers: IFN-γ: Forward: 5'-GCTCTGGAGACAATGAAAGCT-3', Reverse: 5'-AAAGAGATAATCTGGCTCTGC-3'; IL-10: Forward: 5'-TGTGTCAGCCCTGAGTAC-3', Reverse: 5'-CACTGACACTTCGCACAA-3'; IL-1β: Forward: 5'-GTGCTGTCGGACCCATATGAG-3', Reverse: 5'-CAGGAAGACAGGCTTGTGCTC-3'; IL-6: Forward: 5'-TCGTGGAAATGAGAAAAGAGTTG-3', Reverse: 5'-TATGCTTAGGCATAACGCACTAGA-3'. And the reaction steps were set up as follows: pre-degeneration at 95°C for 10 min, these two steps repeated for 40 cycles: degeneration at 95°C for 15 s, extend 60°C for 1 min, fusion curve analysis: 95°C for 15 s, 60°C for 1 min, 95°C for 15 s and 60°C for 15 s. GAPDH was used as an internal control, and data were analysed using 2^ΔΔCT method according to the previous study [27].

**Western blotting analysis**

Brain tissues were lysed with lysis buffer (8 M Urea, 50 mM IAA, 10 mM DTT and proteinase inhibitor cocktail). After being centrifuged at 12000 rpm for 10 min, proteins were collected and concentration of proteins was determined using BCA assay. 60 μg protein samples were separated using 10% SDS-PAGE electrophoresis, after that proteins were transferred onto a nitrocellulose membrane using a semi-dry trans blottor. Then, membranes were blocked with 5% skim milk followed by incubation with primary antibodies (1: 2000) overnight at 4°C. After incubation, membranes were incubated with secondary antibody (1 : 5000) for 1 h at room temperature. Grey value of each protein was detected using chemiluminescent immunoassay, and GAPDH was used as an internal control.

**Enzyme-linked immunosorbent assay (ELISA)**

Serum samples collected from mice and male TBI patients were collected to perform the ELISA experiments (n = 20). The average age of TBI patients is 49.5 ±8.5 years old, and the average age of the male normal control group (n = 20) is 46.7 ±7.7 years old. Patients with a definite history of craniocerebral trauma and without other operation history recently were brought into this experiment. Patients with severe dysfunction in the major organ (such as the heart, liver, lung and kidney), patients with injury in other parts of the body and patients with a previous history of craniocerebral trauma were excluded from this experiment. And ELISA experiments were performed according to the protocol. Briefly, serum samples, standards and reaction buffer were added into each well, and incubated at room temperature for 3 h, after being washed with washing buffer, TMB substrate solution was added into each well and incubated at room temperature for 10 min. After stop solution was added, the optical density was detected at an appropriate wave length using a spectrophotometer (Multiskan GO, Thermo). And data were normalized with the corresponding control group.

**Statistical analysis**

Data were presented as mean ± SD, each experiment was repeated for three times independently. One-way ANOVA was used to compare the differences between groups, p < 0.05 was set as a statistical difference.

**Results**

**Concentration of oxidative stress response related molecules in serum samples of TBI patients**

As shown in Figure 1, the relative concentrations of ROS in normal patients and TBI patients were...
1.00 ± 0.06, 1.82 ± 0.10, respectively. The concentrations of SOD1 in these groups were 2.64 ± 0.19, 1.42 ± 0.12, respectively. The concentrations of MDA in these groups were 1.00 ± 0.05, 1.36 ± 0.07, respectively. The relative concentrations of NADPH in these groups were 1.00 ± 0.05, 1.51 ± 0.13, respectively. Relative concentrations of ROS, MDA and NADPH were significantly increased in serum samples of TBI patients, and the concentration of SOD1 was significantly decreased in TBI patients, indicating that TBI patients were under an oxidative stress status.

**Concentration of oxidative stress response related molecules in serum samples of mice**

As shown in Figure 2, the concentrations of ROS in CG, CT, CO and CI groups were 1.00 ± 0.08, 0.71 ± 0.06, 0.44 ± 0.04 and 1.24 ± 0.11, respectively. The relative concentrations of ROS in CT and CO groups were significantly decreased and in the CI group it was significantly increased compared with the CG group (p < 0.05), and was significantly decreased in the CO group and significantly increased in the CI group compared with the CT group (p < 0.05). The concentrations of SOD1 in these groups were 0.72 ± 0.07, 1.15 ± 0.12, 1.56 ± 0.14 and 0.77 ± 0.06 ng/ml, respectively. The relative concentrations of SOD1 in these groups were 0.72 ± 0.07, 1.15 ± 0.12, 1.56 ± 0.14 and 0.77 ± 0.06 ng/ml, respectively. The relative concentrations of SOD1 were significantly decreased in serum samples of TBI patients, and the concentration of SOD1 was significantly increased in serum samples of TBI patients, indicating that TBI patients were under an oxidative stress status.

**Expression of inflammation response related genes in brain tissues**

As shown in Figure 3, the expressions of inflammation response related genes in brain tissues were
PARP1 might enhance the therapeutic effect of tetrahydroxystilbene glucoside in traumatic brain injury via inhibition of Ras/JNK signalling pathway.

...detected using the qPCR method. The expressions IFN-γ in CG, CT, CO and CI groups were 0.52 ±0.04, 0.87 ±0.06, 1.24 ±0.11 and 0.56 ±0.04, respectively. The expression of IFN-γ was significantly increased in the CT and CO groups compared with the CG group (p < 0.05), and significantly increased in the CO group and significantly decreased in the CI group (p < 0.05) compared with the CT group. The expressions of IL-1β in these groups were 1.27 ±0.13, 0.92 ±0.10, 0.61 ±0.05 and 1.19 ±0.11, respectively. The expression of IL-1β was significantly decreased in the CT and CO groups compared with the CG group (p < 0.05), and significantly decreased in the CO group and significantly increased in the CI group (p < 0.05) compared with the CT group. The expressions of IL-6 in these groups were 1.34 ±0.14, 1.05 ±0.09, 0.74 ±0.06 and 1.28 ±0.12, respectively. The expression of IL-1β was significantly decreased in the CT and CO groups compared with the CG group (p < 0.05), and significantly decreased in the CO group and significantly increased in the CI group (p < 0.05) compared with the CT group. The expressions of IL-10 in these groups were 0.64 ±0.05, 0.98 ±0.09, 1.47 ±0.13 and 0.72 ±0.07, respectively. The change in the expression of IL-10 presented a similar trend with interferon γ (IFN-γ).

**Expression of PARP1 in each group of the mice model**

As shown in Figure 4, the expression levels of PARP1 in brain tissues of normal, PARP1 inhibition and PARP1 overexpression group of mice without TSG treatment were 0.75 ±0.06, 0.58 ±0.05 and 1.14 ±0.10, respectively. The expression of PARP1 was significantly decreased in the inhibition group (p < 0.05) and significantly increased in the overexpression group (p < 0.05). And after TSG treatment, the expressions of PARP1 in CG, CT, CI and CO groups were 0.37 ±0.03, 0.68 ±0.06, 0.83 ±0.07 and 0.37 ±0.03, respectively. The expression of PARP1 was significantly increased in the CT and CO group (p < 0.05) and significantly decreased in the CI group (p < 0.05) compared with the CG group, and significantly increased in the CO group (p < 0.05) and significantly decreased in the CI group (p < 0.05) compared with the CT group.

**Expression of apoptosis related proteins and anti-oxidative enzymes in each group of the mice model**

As shown in Figure 5, the expressions of NOS in CG, CT, CO and CI group were 5.63 ±0.47, 4.22 ±0.35, 2.47 ±0.32, respectively.
±0.21 and 5.60 ±0.47, respectively. The expression of NOS was significantly decreased in CT and CO groups compared with the CG group (p < 0.05), and significantly decreased in the CO group and significantly increased in the CI group (p < 0.05) compared with the CT group. The expressions of NOX4 in these groups were 1.69 ±0.14, 1.69 ±0.14, 1.35 ±0.11 and 2.14 ±0.18, respectively. The expression of NOX4 was significantly decreased in the CO group and significantly increased in the CI group (p < 0.05) compared with the CG and CT group. The expressions of catalase in these groups were 1.14 ±0.10, 1.84 ±0.15, 1.91 ±0.16 and 1.19 ±0.10, respectively. The expression of catalase was significantly increased in the CT and CO group (p < 0.05) compared with the CG group, and significantly decreased in the CI group (p < 0.05) compared with the CT group. The expressions of TRX in these groups were 0.62 ±0.05, 0.92 ±0.08, 1.39 ±0.12 and 0.27 ±0.02, respectively. The change in expression of TRX presented a similar trend with NOS. The expressions of Bcl-2 in these groups were 1.04 ±0.09, 1.54 ±0.13, 1.87 ±0.16 and 1.03 ±0.09, respectively. The expression of Bcl-2 was significantly increased in the CT and CO group (p < 0.05) compared with the CG group, and significantly increased in the CO group and significantly decreased in the CI group (p < 0.05) compared with the CT group. The ratio of activated caspase-3/caspase-3 in these groups were 1.51 ±0.13, 1.17 ±0.10, 0.56 ±0.05 and 1.53 ±0.13, respectively. The expressions of caspase-9 in these groups were 1.19 ±0.10, 0.69 ±0.06, 0.33 ±0.03 and 1.13 ±0.09, respectively. The change in expression of caspase-3 and caspase-9 was significantly decreased in the CT and CO group (p < 0.05) compared with the CG group, and significantly decreased in the CO group and significantly increased in the CI group (p < 0.05) compared with the CT group.

**Fig. 3.** Concentration of oxidative stress response related molecules in serum samples of a mice model. **A)** Concentration of ROS in serum samples. **B)** Concentration of SOD1 in serum samples. **C)** Concentration of MDA in serum samples. **D)** Expression of NADPH in serum samples. Data were presented as mean ±SD. Each experiment was repeated for three times independently. *p < 0.05 compared with the CG group, #p < 0.05 compared with the CT group.
PARP1 might enhance the therapeutic effect of tetrahydroxystilbene glucoside in traumatic brain injury via inhibition of Ras/JNK signalling pathway.

Activation of Ras/JNK signalling pathway in each group of the mice model

As shown in Figure 6, the activation of Ras/JNK signalling pathway was detected using western blotting analysis. The expressions of Rho in CG, CT, CO and CI groups were 0.92 ±0.08, 0.84 ±0.07, 0.32 ±0.03 and 1.16 ±0.10, respectively. The expression of Rho was significantly decreased in the CO group (p < 0.05) and significantly increased in the CI group (p < 0.05) compared with the CG and CT group. The expressions of Ras in these groups were 0.75 ±0.06, 0.47 ±0.04, 0.20 ±0.02 and 1.00 ±0.08, respectively. The expression of Ras was significantly decreased in the CT and CO group (p < 0.05) compared with the CG group, and significantly increased in the CI group (p < 0.05) compared with the CG group. And it was significantly decreased in the CO group (p < 0.05) and significantly increased in the CI group (p < 0.05) compared with the CT group. The expressions of Rac1 in these groups were 1.17 ±0.10, 0.98 ±0.08, 0.60 ±0.05 and 1.34 ±0.11. The expression of Rac1 was significantly decreased in the CO group (p < 0.05) compared with the CG and CT group, and was significantly increased in the CI group (p < 0.05) compared with the CT group. The ratios of p-MEK1/MEK1 in these groups were 1.60 ±0.13, 1.69 ±0.14, 1.30 ±0.11 and 1.95 ±0.16, respectively. The ratio of p-MEK1/MEK1 was significantly decreased in the CO group (p < 0.05) and significantly increased in the CI group (p < 0.05) compared with the CT group. The ratios of p-MEK4/MEK4 in these groups were 1.17 ±0.10, 0.70 ±0.06, 0.31 ±0.03 and 1.05 ±0.09, respectively. The ratio of p-MEK4/MEK4 was significantly decreased in the CT and CO group (p < 0.05).

Fig. 4. Expression of inflammatory response related genes in brain tissues of a mice model. A) Expression of IL-1β in brain tissue of a mice model. B) Expression of IL-6 in brain tissue of a mice model. C) Expression of IL-10 in brain tissue of a mice model. D) Expression of IFN-γ in brain tissue of a mice model. Data were presented as mean ±SD. Each experiment was repeated for three times independently. *p < 0.05 compared with the CG group, #p < 0.05 compared with the CT group.
compared with the CG group, and was significantly decreased in the CO group ($p < 0.05$) and significantly increased in the CI group ($p < 0.05$) compared with the CT group. The ratios of $p$-JNK/JNK in these groups were $1.32 \pm 0.11$, $1.25 \pm 0.10$, $0.91 \pm 0.08$ and $1.75 \pm 0.15$, respectively. The ratio of $p$-JNK/JNK was significantly decreased in the CO group ($p < 0.05$) and significantly increased in the CI group ($p < 0.05$) compared with the CG and CT group.

**Discussion**

Traumatic brain injury (TBI) is a great threat in global health care, with more than 27 million new cases each year [11]. In the process of TBI, long axons are especially susceptible to compression and tension, resulting in axonal injury. Besides, inflammation and degeneration process in neurons lasts for years after TBI, causing chronic symptoms in TBI patients [13]. There is plenty of treatments for TBI nowadays, including traditional medicine treatment, transplanting neural stem cells (NSCs) and bone marrow-derived mesenchymal stem cells [14]. Among them, tetrahydroxystilbene glucoside (TSG) is extracted from traditional Chinese medicine, and has anti-atherosclerosis, hepatoprotective and hypolipidemic effects. However, the effect of TSG in TBI was not clear. Poly-ADP-ribose polymerase 1 (PARP1) is a multi-function enzyme, regulates intracellular processes, including DNA repair, signalling transduction and metabolism via interaction with other proteins and DNA, promoting DNA repair [36].

Rho and Rac1 are family members of GTPases, directly regulate the function of cellular process [23]. Binding of Rho, Rac1 or Cdc43 to p21-binding domain (PBD) of group I PAKs induces the phosphory-
PARP1 might enhance the therapeutic effect of tetrahydroxystilbene glucoside in traumatic brain injury via inhibition of Ras/JNK signalling pathway

lation and activation of multiple downstream molecules [4], further promotes the polymerization of actin and the reduction in expression of PTEN [19], resulting in the activation of the target effector of MAPK, such as ERK and JNK [40]. Ras/mitogen-activated protein kinase (MAPK) signalling pathway regulates the cell proliferation, and has been considered as a key molecular pathway in development of disease both in experimental models and humans [2,21]. Ras/MAPK signalling pathway is activated by multiple cytokines, insulin and oxidative stress. Activated Ras would further activate Raf kinase, leading to the phosphorylates of further kinase cascades, MEK1 and MKK4. This process would lead to the phosphorylate of downstream effector molecules, including extracellular signal regulated kinases (ERKs) and c-Jun N-terminal kinase (JNK), regulates the expression of specific genes [33]. However, the effect of JNK in cellular apoptosis process remains controversial. There are studies reporting that TNF-α induced the activation of JNK, which leads to the cellular survival or differentiation via increasing expression of anti-apoptotic genes induced by NF-κB signalling pathway [8]. But there are also studies indicating that activation of JNK further activates the apoptosis process. The previous study indicated that JNK could directly inhibit the expression of Bcl-2 [38]. Besides, activated JNK were further translocated into mitochondria and induced the release of cytochrome c [6], and this effect might be mediated by activation of caspase cascade [9]. In this study, we found that TSG treatment decreased the expression of p-JNK, p-MKK4, p-MEKK1 and Rho family proteins, indicating that TSG treatment inhibited the activation of Ras/MAPK signalling pathway. We also found that these effects could be enhanced by over-

Fig. 6. Activation of the Ras/JNK signalling pathway in brain tissues of a mice model. Data were presented as mean ±SD. Each experiment was repeated for three times independently. *p < 0.05 compared with the CG group, #p < 0.05 compared with the CT group.
accumulation of ROS and cellular apoptosis in cul-

and methionine sulfoxide reductases. A previously function 

performed in mitochondria and performs an anti-oxidative 

system plays an important role in preventing cellular oxidative stress stimulation. The thioredoxin 

mice, TRX reductase and the cellular oxidative stress stimulation. The thioredoxin 

TRX2 deficiency leads to the expression of NOX2 was significantly decreased, 

ment alone could not down-regulate the expression 

Superoxide injury is more dependent on NOX 

the expression of NOS was increased with the occurrence of cellular damage 

Cytochrome c further interacted with APAF1 (apoptotic 

expression of PARP1. Considering the former results 

Oxidative stress and ROS production were the 

the main causes of cellular damage in the TBI model, the 

previous study found that the expression of NOX2 

resulting in a negative regulation manner, enhance the therapeutic effect of TSG. 

oxidative stress stimulation. The thioredoxin 

of pro-apoptotic proteins, including cytochrome c. Cytochrome c further interacted with APAF1 (apoptotic protease activating factor 1), then activated the caspase-9 from the apoptosome [16]. Activated caspase-9 further led to the activation of downstream executioner molecules, including caspase-3, 6 and 7, inducing the cellular apoptosis [10]. The expression of Bcl-2 was increased and the expression of caspase cascades was decreased after TSG treatment, indicating that TSG treatment improves the survival of neural cells and PARP1 overexpression would enhance this effect.

Conclusions

In this study, we noticed that TSG treatment reduces the oxidative stress, inflammatory and apoptosis response in TBI patients and a TBI mouse model, and these effects might be mediated by inhibition of the Ras/JNK signalling pathway. PARP1
overexpression would enhance these effects. The results of our present study indicated that PARP1 might be a therapeutic target of TBI, and we noticed that overexpression of PARP1 presented a promising effect in improving the molecular function in a mice model. However, more experiments on the animal model and TBI patients in our following research are still needed in order to apply this finding in treatment of TBI patients.

Disclosure

The authors report no conflict of interest.

References


